Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

OsteoarthritisRheumatoid ArthritisSystemic Lupus Erythematosus
Do you want to read an article? Please log in or register.